Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Exploratory Study to Evaluate the Effect of SYN111 (Rufinamide) in Patients With Generalized Anxiety Disorder (GAD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00595231
Recruitment Status : Completed
First Posted : January 16, 2008
Results First Posted : January 23, 2019
Last Update Posted : February 27, 2019
Sponsor:
Collaborator:
Syneos Health
Information provided by (Responsible Party):
Biotie Therapies Inc.

Brief Summary:
A Multi-Centered Randomized, Double-Blind, Placebo-Controlled, Phase 2, Exploratory Study to Evaluate the Effect of Rufinamide on Anxiety in Patients with Moderate to Severe Generalized Anxiety Disorder.

Condition or disease Intervention/treatment Phase
Generalized Anxiety Disorder Drug: SYN111 Drug: Placebo Phase 2

Detailed Description:
This was an exploratory study to evaluate the effect of 500 or 1000 mg per day for 8 weeks of Rufinamide compared to placebo on measures of anxiety in patients with Generalized Anxiety Disorder, and to determine tolerability of Rufinamide in this population.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 239 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multi-Center,Randomized, Double-Blind, Placebo-Controlled, Phase 2, Exploratory Study to Evaluate the Effect of Rufinamide on Anxiety in Patients With Moderate to Severe Generalized Anxiety Disorder
Study Start Date : March 2008
Actual Primary Completion Date : October 2008
Actual Study Completion Date : October 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Anxiety
Drug Information available for: Rufinamide

Arm Intervention/treatment
Experimental: SYN111
500 mg 1 week, followed by 1000 mg for 7 weeks
Drug: SYN111
500 mg for 1 week followed by 1000 mg for 7 weeks
Other Name: Rufinamide

Placebo Comparator: Placebo
0 mg tablets
Drug: Placebo
0 mg tablets




Primary Outcome Measures :
  1. Change From Baseline in Hamilton Anxiety Scale (HAMA) - Total Score: Summary Statistics - Observed [ Time Frame: 8 Weeks ]
    The Hamilton Anxiety Scale is a 14-item test measuring the severity of anxiety symptoms. It provides measures of overall anxiety, psychic anxiety (mental agitation and psychological distress), and somatic anxiety (physical complaints related to anxiety). The interviewer then rated the individuals on a 5-point scale for each of the 14 items. Seven of the items specifically address psychic anxiety and the remaining 7 items address somatic anxiety. The total anxiety score ranges from 0 to 56. The 7 psychic anxiety items elicit a psychic anxiety score that ranges from 0 to 28. The remaining 7 items yield a somatic anxiety score that also ranges from 0 to 28. A score of 17 or less indicates mild anxiety severity. A score from 18 to 24 indicates mild to moderate anxiety severity, a score of 25 to 30 indicates a moderate to severe anxiety and lastly a score of 31-56 is very severe. HAM-A total score is the sum of items 1 - 14.

  2. Change From Baseline in Hospital Anxiety and Depression Scale (HADS). Summary Statistics [ Time Frame: 8 Weeks ]
    The Hospital Anxiety and Depression Scale is a self screening questionnaire for depression and anxiety. It consists of 14 questions, seven for anxiety and seven for depression. The 14 statements are relevant to either generalized anxiety (7 statements) or 'depression' (again 7). Each question has 4 possible responses. Responses are scored on a scale from 3 to 0. The maximum score is therefore 21 for depression and 21 for anxiety. A score of 11 or higher indicates the probable presence of the mood disorder with a score of 8 to 10 being just suggestive of the presence of the respective state. The 2 subscales, anxiety and depression, have been found to be independent measures. In its current form the HADS is now divided into 4 ranges: normal (0-7), mild (8-10), moderate (11-15) and severe (16-21). Anxiety score = sum of items 1, 3, 5, 7, 9, 11, and 13. Depression score = sum of items 2, 4, 6, 8, 10, 12, and 14.

  3. Change From Baseline in Montgomery-Asberg Depression Scale (MADRS) Summary Statistics. [ Time Frame: 8 Weeks ]
    The MADRS (Montgomery and Asberg 1979) is a clinician-rated instrument that measures the presence and severity of depression. This instrument consists of 10 items. Each item is rated on a defined step scale of 0 to 6 with anchors at 2-point intervals. The MADRS total score is the sum of the 10 items and ranges from 0 to 60. A high numeric rating shows a greater degree of symptom severity.

  4. Change From Baseline in Clinical Global Impression Scale for Severity of Illness: (CGI-S) [ Time Frame: 8 weeks ]
    Severity of illness is the first scale in the CGI. A rating is filled in by the investigator at the start of treatment based on a 0-7 point weighted scale. It goes from not assessed (0), to among the most extremely ill patients (7).

  5. Change From Baseline Raskin Depression Scale. [ Time Frame: 8 weeks ]
    It explores the extent to which an individual demonstrates depression on three sub-scales (rated 1-5): verbal self-report, behavior and secondary symptoms of depression. Scores range from 3-15, with higher scores indicating greater severity.

  6. Change From Baseline in Covi Anxiety Scale (CAS) - Index Total Score: Summary Statistics Observed [ Time Frame: 8 weeks ]

    The Covi Anxiety Scale is a simple 3 item scale for the assessment of severity of anxiety symptoms. The scale measures 3 dimensions: verbal report, behavior and somatic symptoms of anxiety. Each item scored on a scale of 1 - 5. (1)not at all, (2)somewhat, (3)moderately, (4) considerably, and (5)very much), hence the scale is a 5- to 15 point range. The three items are the patient's verbal report (feeling shaky, jittery, jumpy), observed behavior consistent with anxiety during the interview (e.g. appearing frightened, shaky, restless) and somatic complains (e.g., sweating, trembling, heart pounding).

    COVI Rating Scale total score is the sum of items 1 - 3.




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Outpatient 18-65
  • Meet Diagnostic and Statistical Manual,(DSM) IV criteria for GAD
  • Have moderate to severe anxiety
  • Sign IRB (Institutional Review Board) approved consent and can comply with visits and procedures
  • Women of childbearing potential must use acceptable method of contraception

Exclusion Criteria:

  • Have diagnosis of adjustment disorder or anxiety disorder Not otherwise specified (NOS)
  • Have diagnosis of specific phobia
  • Have diagnosis of antisocial personality disorder or other Axis II Disorder
  • Have diagnosis of substance abuse disorder within 3 months of study entry
  • Have diagnosis of major depressive disorder or panic disorder within 6 months of study entry
  • Have diagnosis of PTSD, eating disorder substance dependence disorder within 12 months of study entry
  • Have diagnosis anytime during lifetime of schizophrenia or other psychotic disorder, bipolar mood disorder, Obsessive-Compulsive Disorder (OCD), psychosurgery
  • Require medication to treat GAD other than study medication
  • Failed to show improvement with past treatment for GAD
  • Excessively consume caffeine
  • Are receiving treatment with prohibited medications
  • Uncontrolled thyroid condition
  • Positive urine drug screen
  • Obese
  • Clinically significant ECG finding
  • Participating in other clinical trial
  • Clinically significant out of range lab value
  • Past exposure to rufinamide
  • Pregnant or nursing females

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00595231


Locations
Layout table for location information
United States, Georgia
Carmen Research
Atlanta, Georgia, United States, 30080
United States, Ohio
Midwest Clinical Research Center
Dayton, Ohio, United States, 45408
Sponsors and Collaborators
Biotie Therapies Inc.
Syneos Health
Investigators
Layout table for investigator information
Study Chair: Christpher Kenney, MD Biotie Therapies Inc.
Layout table for additonal information
Responsible Party: Biotie Therapies Inc.
ClinicalTrials.gov Identifier: NCT00595231    
Other Study ID Numbers: SYN111-CL03
First Posted: January 16, 2008    Key Record Dates
Results First Posted: January 23, 2019
Last Update Posted: February 27, 2019
Last Verified: February 2019
Keywords provided by Biotie Therapies Inc.:
GAD
Additional relevant MeSH terms:
Layout table for MeSH terms
Anxiety Disorders
Mental Disorders
Rufinamide
Anticonvulsants
Voltage-Gated Sodium Channel Blockers
Sodium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action